X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Wyost (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is approved for patients with bone metastases from solid tumors.
Lead Product(s): Denosumab
Therapeutic Area: Oncology Product Name: Wyost
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Cimerli
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Coherus Biosciences
Deal Size: $170.0 million Upfront Cash: $170.0 million
Deal Type: Divestment March 04, 2024
Details:
The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar product utilized in the treatment of patients diagnosed with breast cancer or metastatic stomach cancer.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Product Name: Ogivri
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Biocon Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 10, 2024
Details:
Tyruko (natalizumab-sztn - biosimilar) is a highly effective anti-α4 integrin monoclonal antibody. It is indicated for the treatment of relapsing-remitting forms of multiple sclerosis.
Lead Product(s): Natalizumab
Therapeutic Area: Neurology Product Name: Tyruko
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Cimerli
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Coherus Biosciences
Deal Size: $170.0 million Upfront Cash: $170.0 million
Deal Type: Divestment January 22, 2024
Details:
The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Endocrinology Product Name: Sandostatin LAR Depot
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Aspen Pharmacare Holdings
Deal Size: $99.9 million Upfront Cash: Undisclosed
Deal Type: Agreement December 04, 2023
Details:
EG12014, biosimilar of trastuzumab, is an anti-HER2 antibody-drug conjugate (ADC) which is being developed for HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Product Name: EG12014
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: EirGenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2023
Details:
Hyrimoz (adalimumab-adaz) binds with specificity to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, which is approved for rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Hyrimoz
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Through the spinoff, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: SB17
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger October 04, 2023
Details:
Through the divestment, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: SB17
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger October 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
